Assessing the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes
Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)
Aristotle University Of Thessaloniki · NCT06890013
This study is testing if measuring blood vessel response can help predict outcomes for patients with serious heart conditions like heart attacks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Aristotle University Of Thessaloniki (other) |
| Locations | 1 site (Thessaloniki) |
| Trial ID | NCT06890013 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the predictive role of flow mediated dilatation (FMD) in patients with acute coronary syndromes, including STEMI and NSTEMI. It will combine FMD assessments with echocardiographic and biochemical indices to enhance understanding of endothelial function in these patients. The study will utilize the novel Cor-IS technology to gather data and insights. Participants will be monitored to assess the relationship between FMD and clinical outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are hospitalized due to acute coronary syndromes.
Not a fit: Patients with rare types of acute coronary syndromes or significant comorbidities that limit their survival may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the predictive capabilities for acute coronary syndromes, leading to better patient management and outcomes.
How similar studies have performed: While the specific approach of this study may be novel, similar studies assessing endothelial function in acute coronary syndromes have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 18 years 2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI) 3. Capability of providing written informed consent 4. Patients able to comply with the follow-up schedule of the study Exclusion Criteria: 1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction 2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome 3. Patients with congenital heart disease 4. Age \> 85 years 5. Patients with end stage chronic kidney disease 6. Patients with active malignancy or autoimmune diseases which limit their survival 7. Patients with expected survival \< 1 year due to other reasons 8. Suboptimal echocardiographic windows 9. Inability to provide written consent 10. Inability to comply with the follow-up schedule of the study 11. Pregnancy 12. Use of intravenous drugs
Where this trial is running
Thessaloniki
- Ippokratio General Hospital — Thessaloniki, Greece (RECRUITING)
Study contacts
- Principal investigator: Christodoulos E. Papadopoulos, PhD — Aristotle University of Thessaloniki, Greece
- Study coordinator: Christodoulos E. Papadopoulos, PhD
- Email: chrpapado@gmail.com
- Phone: 2313312343
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Coronary Syndromes, Flow Mediated Dilation, Endothelial Function, acute coronary syndrome, endothelial dysfunction, biomarker, flow mediated dilatation